Tag:

drug prices

Unclear Terms, Unequal Burdens: Compliance Risks in Pharma’s Most-Favored-Nation Agreements

The White House has secured pricing agreements from 26 drugmakers in exchange for relief from new tariffs on imported drugs. Since September 2025, Pfizer and other large drug manufacturers have signed these agreements, referred to as most-favored-nation agreements (MFN Agreements). Under them, drug manufacturers commit to lowering U.S. drug prices to match the lowest prices paid in other developed nations, and in return they receive relief from the new tariffs. As of August 2026, 26 companies, encompassing 89% of the branded drug market, have entered into an MFN Agreement. However, many smaller drug manufacturers are left in the dark about how to qualify for that relief, and because the agreements are negotiated privately and the relief ends in January 2029, those companies face real compliance risk. To address this, HHS should publish standard MFN Agreement terms, HHS and the Commerce Department should set clear rules and deadlines for exemptions, and Congress should decide whether these commitments last beyond this administration.